Medicinal Chemistry 3 Group

Ismaela joined the ICR in October 2020 as a Data Manager in the In Silico Medicinal Chemistry Team. He previously worked in the Global Clinical Trial Unit at Liverpool School of Tropical Medicine, Medical Research Council at LSHTM-Gambia and also at Noguchi Memorial Institute for Medical Research-Ghana. At the ICR, Ismaela is a core member of CTU-Cheminformatics resolving Dotmatics problems and supporting Dotmatics activities.

I am a medicinal chemist with a background in both anticancer and antimicrobial drug discovery. I joined the newly established Children’s Brain Tumour Centre of Excellence (CBTCE) in November 2019 and have been working in collaboration with the University of Cambridge to initiate the Centre’s first research projects. The aim of the CBTCE is to transform the way we develop treatments for children with brain tumours. I am interested in developing new small molecule therapeutics and chemical probes to interrogate cancer biology.

Daniella is a PhD student in both the Medicinal Chemistry 4 and the In-Silico Medicinal Chemistry teams. Her PhD project will look at computational approaches to predict the water networks in the binding sites of proteins and is carried out in collaboration with AstraZeneca as part of the industrial CASE (iCASE) studentship scheme.

Andrew joined the ICR initially as a post-doctoral scientist before moving to industry to work as a senior medicinal chemist. He re-joined ICR in March 2021 as a Medicinal Chemist in the Centre for Cancer Drug Discovery. As part of his role, Andrew designs and synthesises compounds for various drug discovery projects. In addition, he has other responsibilities within the wider Medicinal Chemistry department including helping run the Medicinal Chemistry 3 lab.

I have worked at the ICR since 2001, first as a Post-doctoral Scientist before progressing to Senior Scientific Officer in 2009. During this time I have contributed to a number of successful drug discovery projects, including HSP90 and CHK1. As well as Medicinal Chemistry, I have an interest in Cheminformatics which has led me to help maintain and develop our Dotmatics databases, ELN and visualisation software.

Alex is a PhD student in Medicinal Chemistry 3. He graduated from the University of York (MChem). He spent his Masters year as a RiCH intern at F. Hoffmann - La Roche working on medicinal chemistry in the neurology field. Alex’s PhD looks at the synthesis and design of small molecules for immuno-oncology applications.

I'm a Medicinal Chemist working for the Chemistry Department. My main role is to synthesise compounds for drug development in which I apply my organic and medicinal chemistry knowledge. I also determine the solubility (by NMR and HPLC) and LogDs of our project compounds, which are important parameters in drug discovery. Apart from my research work at the ICR I'm also the Technician Commitment and Social Media representative of the Scientific Officers Association. My other interests involve the Athena Swan Programme and Public Engagement activities.

Paul joined the ICR as a postdoctoral training fellow in the In Silico Medicinal Chemistry Team in 2021. He obtained his PhD in Canada at the University of Windsor in computational chemistry focusing on mechanistic studies of sulphur-containing enzymes. He is currently providing computational chemistry support to a number of drug discovery projects in the CTU, with a focus on targets for RNA helicases and immune response.

I am a medicinal chemist working within the Children's Brain Tumour Centre of Excellence on the synthesis of new compounds for the treatment of paediatric ependymomas.

Andrea joined the ICR in July 2021 as a Postdoctoral Training Fellow in the In Silico Medicinal Chemistry Team. He previously worked in the Medicinal Chemistry group at the Research Centre for Natural Sciences in Budapest, where he completed his PhD focusing on the development of covalent docking protocols for drug discovery. At the ICR, Andrea applies computational methods to support the design of protein degraders and inhibitors as new cancer treatments.